The triple-SN MG patients were treated with symptomatic treatment with acetylcholinesterase inhibitors, associated with corticosteroids in 25% of patients, and azathioprine plus corticosteroids in 75% of patients. The gene discussed is ACHE; the disease is myasthenia gravis.